FDA sends J&J CRL on Xarelto for stent thrombosis

Eric Palmer

The FDA keeps offering up tough news to Johnson & Johnson for its warfarin replacement, . It has twice turned it down for treatment of acute coronary syndrome (ACS), and today the company said it had a complete response letter for use of the bloodthinner to prevent in patients with ACS.

FiercePharma News

Share This Post

Related Articles

Leave a Reply

© 2019 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS